David Oxley

David Oxley has a diverse work experience spanning over two decades. David'smost recent position was as the Chief Business Officer at BIORCHESTRA Co., Ltd., a biotherapeutics company focused on degenerative and rare Central Nervous System diseases. Prior to that, they served as the President International at Exopharm Ltd, where they led the external commercial strategy and partnerships for the company. Before Exopharm, they worked as the Sr. Vice President of Business Development & Licensing at Mesoblast Limited, where they led global business development strategy and engagement.

In addition to their corporate roles, David Oxley also has experience as an entrepreneur, having founded David Oxley LLC. David has also served as a Board Director at TB Biosciences, Inc., a company focused on creating a point-of-care test for Tuberculosis diagnosis. Furthermore, they worked at Lorem Vascular, Pty. Ltd. as the Interim CEO, leading the company's efforts in the field of regenerative medicine.

Earlier in their career, David Oxley held senior leadership positions at Cytori, Trinity Biotech, and OraSure Technologies, where they contributed to the development and commercialization of medical technologies. Prior to that, they worked as a Financial Consultant at Wells Fargo.

Overall, David Oxley's work experience showcases their expertise in business development, licensing, strategic partnerships, and commercialization within the biotech and healthcare industries.

David Oxley obtained a Master's degree in Government Public Health from The Johns Hopkins University, which they completed between 1996 and 1998. In addition, they obtained certifications in Series 7 and 63 from the Financial Industry Regulatory Authority (FINRA) in March 2000.